Adrenalitis and anasarca in idiopathic multicentric Castleman's disease
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:397 |
---|---|
Enthalten in: |
Lancet (London, England) - 397(2021), 10286 vom: 08. Mai, Seite 1749 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Chen, Luke Y C [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 24.12.2021 Date Revised 04.11.2022 published: Print Citation Status MEDLINE |
---|
doi: |
10.1016/S0140-6736(21)00674-7 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM32516763X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM32516763X | ||
003 | DE-627 | ||
005 | 20231225191848.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/S0140-6736(21)00674-7 |2 doi | |
028 | 5 | 2 | |a pubmed24n1083.xml |
035 | |a (DE-627)NLM32516763X | ||
035 | |a (NLM)33965090 | ||
035 | |a (PII)S0140-6736(21)00674-7 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Chen, Luke Y C |e verfasserin |4 aut | |
245 | 1 | 0 | |a Adrenalitis and anasarca in idiopathic multicentric Castleman's disease |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 24.12.2021 | ||
500 | |a Date Revised 04.11.2022 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
650 | 4 | |a Case Reports | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Video-Audio Media | |
650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
650 | 7 | |a Antineoplastic Agents |2 NLM | |
650 | 7 | |a Antineoplastic Agents, Hormonal |2 NLM | |
650 | 7 | |a Azetidines |2 NLM | |
650 | 7 | |a Immunosuppressive Agents |2 NLM | |
650 | 7 | |a Janus Kinase Inhibitors |2 NLM | |
650 | 7 | |a Purines |2 NLM | |
650 | 7 | |a Pyrazoles |2 NLM | |
650 | 7 | |a Reticulin |2 NLM | |
650 | 7 | |a Sulfonamides |2 NLM | |
650 | 7 | |a Bortezomib |2 NLM | |
650 | 7 | |a 69G8BD63PP |2 NLM | |
650 | 7 | |a Dexamethasone |2 NLM | |
650 | 7 | |a 7S5I7G3JQL |2 NLM | |
650 | 7 | |a Cyclosporine |2 NLM | |
650 | 7 | |a 83HN0GTJ6D |2 NLM | |
650 | 7 | |a baricitinib |2 NLM | |
650 | 7 | |a ISP4442I3Y |2 NLM | |
650 | 7 | |a siltuximab |2 NLM | |
650 | 7 | |a T4H8FMA7IM |2 NLM | |
700 | 1 | |a Skinnider, Brian F |e verfasserin |4 aut | |
700 | 1 | |a Wilson, Don |e verfasserin |4 aut | |
700 | 1 | |a Fajgenbaum, David C |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Lancet (London, England) |d 1945 |g 397(2021), 10286 vom: 08. Mai, Seite 1749 |w (DE-627)NLM000473936 |x 1474-547X |7 nnns |
773 | 1 | 8 | |g volume:397 |g year:2021 |g number:10286 |g day:08 |g month:05 |g pages:1749 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/S0140-6736(21)00674-7 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 397 |j 2021 |e 10286 |b 08 |c 05 |h 1749 |